Ublituximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ublituximab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
47
Registered trials
77
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ublituximab can convert its Monoclonal antibody profile and CD20 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ublituximab (query alias: Ublituximab) |
|---|---|
| Modality / target | Monoclonal antibody; CD20; CD20 inhibitors, ADCC, CD20-directed cytolytic effects |
| Highest global status | Approved |
| Originator | rEVO Biologics, Inc., LFB Biotechnologies SASU |
| Active developers | Accelagen, TG Therapeutics, Inc., AstraZeneca PLC |
The MCP disease footprint includes Multiple sclerosis relapse, Multiple Sclerosis, Relapsing-Remitting, Myasthenia Gravis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07389590 | Phase 4 | Recruiting | 50 | Proportion of Patients with Wearing-Off |
| NCT07503873 | Phase 2 | Recruiting | 350 | Part 2: Area under the curve (AUC) From Week 0 to Week 12 [AUC(0-W12)] of Ublituximab |
| NCT07673744 | Phase 2 | Recruiting | 120 | Time to Onset of a Clinical Worsening Event |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis
Phase 3; n=994; evaluation: Positive. Reported fields: ARR = 0.334 year ; ARR = 0.188 year ; ARR = 0.081 year
Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study
Not Applicable; n=221; evaluation: Positive. Reported fields: TSQM-9 scores(Week 24) = 97.1 %
Five Years of Ublituximab in Multiple Sclerosis
Phase 3; n=851; evaluation: Positive. Reported fields: AE = serious infections (excluding COVID events) of 2.10 (UBL-UBL) and 2.58 (TER-UBL). ; AE = serious infections (excluding COVID events) of 2.10 (UBL-UBL) and 2.58 (TER-UBL).
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ublituximab addresses Multiple sclerosis relapse, Multiple Sclerosis, Relapsing-Remitting, Myasthenia Gravis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-08-01 | TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy) | Approved | US$140.0M upfront; US$492.5M milestones; US$645.0M stated total |
| 2012-11-15 | TG Therapeutics Announces Exclusive Licensing Agreement With Ildong Pharmaceutical Co., Ltd. for Development and Commercialization of Ublituximab (TGTX-1101) in South Korea and Southeast Asia | Phase 1/2 | US$2.0M upfront |
| 2012-03-02 | TG Therapeutics Completes Licensing Agreement With LFB Biotechnologies for the Development of Ublituximab | Phase 1/2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Subcutaneous formulations of Anti-CD20 antibody”. The milestone feed surfaced a patent-application signal described as “Therapeutic combination of an AKT inhibitor, a BCL-2 inhibitor, and an Anti-CD20 antibody”. The milestone feed surfaced a patent-application signal described as “CD20 antibody AAV vectors and methods of use thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
